Hida T - Search Results

1

Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study.

Dietel M, Savelov N, Salanova R, Micke P, Bigras G, Hida T, Antunez J, Guldhammer Skov B, Hutarew G, Sua LF, Akita H, Chan OSH, Piperdi B, Burke T, Khambata-Ford S, Deitz AC. Dietel M, et al. Among authors: hida t. Lung Cancer. 2019 Aug;134:174-179. doi: 10.1016/j.lungcan.2019.06.012. Epub 2019 Jun 12. Lung Cancer. 2019. PMID: 31319978

2

Preferential expression of c-kit protooncogene transcripts in small cell lung cancer.

Sekido Y, Obata Y, Ueda R, Hida T, Suyama M, Shimokata K, Ariyoshi Y, Takahashi T. Sekido Y, et al. Among authors: hida t. Cancer Res. 1991 May 1;51(9):2416-9. Cancer Res. 1991. PMID: 1707753

3

Expression and amplification of myc gene family in small cell lung cancer and its relation to biological characteristics.

Takahashi T, Obata Y, Sekido Y, Hida T, Ueda R, Watanabe H, Ariyoshi Y, Sugiura T, Takahashi T. Takahashi T, et al. Among authors: hida t. Cancer Res. 1989 May 15;49(10):2683-8. Cancer Res. 1989. PMID: 2540905

4

Ectopic expression of c-kit in small-cell lung cancer.

Hida T, Ueda R, Sekido Y, Hibi K, Matsuda R, Ariyoshi Y, Sugiura T, Takahashi T, Takahashi T. Hida T, et al. Int J Cancer Suppl. 1994;8:108-9. doi: 10.1002/ijc.2910570723. Int J Cancer Suppl. 1994. PMID: 7515024

5

Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit protooncogene.

Sekido Y, Takahashi T, Ueda R, Takahashi M, Suzuki H, Nishida K, Tsukamoto T, Hida T, Shimokata K, Zsebo KM, et al. Sekido Y, et al. Among authors: hida t. Cancer Res. 1993 Apr 1;53(7):1709-14. Cancer Res. 1993. PMID: 7680956

6

Serum glutathione S-transferase-pi level as a tumor marker for non-small cell lung cancer. Potential predictive value in chemotherapeutic response.

Hida T, Kuwabara M, Ariyoshi Y, Takahashi T, Sugiura T, Hosoda K, Niitsu Y, Ueda R. Hida T, et al. Cancer. 1994 Mar 1;73(5):1377-82. doi: 10.1002/1097-0142(19940301)73:5<1377::aid-cncr2820730511>3.0.co;2-n. Cancer. 1994. PMID: 8111704 Clinical Trial.

7

The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status.

Suzuki T, Nakagawa T, Endo H, Mitsudomi T, Masuda A, Yatabe Y, Sugiura T, Takahashi T, Hida T. Suzuki T, et al. Among authors: hida t. Lung Cancer. 2003 Oct;42(1):35-41. doi: 10.1016/s0169-5002(03)00278-2. Lung Cancer. 2003. PMID: 14512185

8

Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer.

Yoshida K, Yatabe Y, Park JY, Shimizu J, Horio Y, Matsuo K, Kosaka T, Mitsudomi T, Hida T. Yoshida K, et al. Among authors: hida t. J Thorac Oncol. 2007 Jan;2(1):22-8. J Thorac Oncol. 2007. PMID: 17410005 Free article. Clinical Trial.

9

Gefitinib for the treatment of non-small-cell lung cancer.

Hida T, Ogawa S, Park JC, Park JY, Shimizu J, Horio Y, Yoshida K. Hida T, et al. Expert Rev Anticancer Ther. 2009 Jan;9(1):17-35. doi: 10.1586/14737140.9.1.17. Expert Rev Anticancer Ther. 2009. PMID: 19105704 Review.

10

Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations.

Yoshida K, Yatabe Y, Park J, Ogawa S, Park JY, Shimizu J, Horio Y, Matsuo K, Mitsudomi T, Hida T. Yoshida K, et al. Among authors: hida t. J Cancer Res Clin Oncol. 2010 Apr;136(4):527-35. doi: 10.1007/s00432-009-0685-2. Epub 2009 Sep 24. J Cancer Res Clin Oncol. 2010. PMID: 19777258

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

656 results

Search Page